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Abstract
What carcinoembryonic antigen level should trigger
further investigation during colorectal cancer follow-up?
A systematic review and secondary analysis of a randomised
controlled trial
Bethany Shinkins,1 Brian D Nicholson,1 Tim James,2 Indika Pathiraja,1
Sian Pugh,3 Rafael Perera,1 John Primrose3 and David Mant1*
1Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK
2Oxford University Hospitals NHS Foundation Trust, Oxford, UK
3Medical Sciences Division, University of Southampton, Southampton, UK
*Corresponding author david.mant@phc.ox.ac.uk
Background: Following primary surgical and adjuvant treatment for colorectal cancer, many patients are
routinely followed up with blood carcinoembryonic antigen (CEA) testing.
Objective: To determine how the CEA test result should be interpreted to inform the decision to
undertake further investigation to detect treatable recurrences.
Design: Two studies were conducted: (1) a Cochrane review of existing studies describing the diagnostic
accuracy of blood CEA testing for detecting colorectal recurrence; and (2) a secondary analysis of data from
the two arms of the FACS (Follow-up After Colorectal Surgery) trial in which CEA testing was carried out.
Setting and participants: The secondary analysis was based on data from 582 patients recruited into the
FACS trial between 2003 and 2009 from 39 NHS hospitals in England with access to high-volume services
offering surgical treatment of metastatic recurrence and followed up for 5 years. CEA testing was
undertaken in general practice.
Results: In the systematic review we identified 52 studies for meta-analysis, including in aggregate 9717
participants (median study sample size 139, interquartile range 72–247). Pooled sensitivity at the most
commonly recommended threshold in national guidelines of 5 µg/l was 71% [95% confidence interval (CI)
64% to 76%] and specificity was 88% (95% CI 84% to 92%). In the secondary analysis of FACS data,
the diagnostic accuracy of a single CEA test was less than was suggested by the review [area under the
receiver operating characteristic curve (AUC) 0.74, 95% CI 0.68 to 0.80]. At the commonly recommended
threshold of 5 µg/l, sensitivity was estimated as 50.0% (95% CI 40.1% to 59.9%) and lead time as about
3 months. About four in 10 patients without a recurrence will have at least one false alarm and six out of
10 tests will be false alarms (some patients will have multiple false alarms, particularly smokers). Making
decisions to further investigate based on the trend in serial CEA measurements is better (AUC for positive
trend 0.85, 95% CI 0.78 to 0.91), but to maintain approximately 70% sensitivity with 90% specificity it is
necessary to increase the frequency of testing in year 1 and to apply a reducing threshold for investigation
as measurements accrue.
Limitations: The reference standards were imperfect and the main analysis was subject to work-up bias
and had limited statistical precision and no external validation.
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Conclusions: The results suggest that (1) CEA testing should not be used alone as a triage test; (2) in year 1,
testing frequency should be increased (to monthly for 3 months and then every 2 months); (3) the threshold
for investigating a single test result should be raised to 10 µg/l; (4) after the second CEA test, decisions
to investigate further should be made on the basis of the trend in CEA levels; (5) the optimal threshold for
investigating the CEA trend falls over time; and (6) continuing smokers should not be monitored with CEA
testing. Further research is needed to explore the operational feasibility of monitoring the trend in CEA levels
and to externally validate the proposed thresholds for further investigation.
Study registration: This study is registered as PROSPERO CRD42015019327 and Current Controlled
Trials ISRCTN93652154.
Funding: The main FACS trial and this substudy were funded by the National Institute for Health Research
Health Technology Assessment programme.
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Plain English summary
Carcinoembryonic antigen (CEA) is a chemical found in the bloodstream. Its level tends to be raised inpeople with cancer of the colon and rectum. It is routinely measured to check for recurrence of cancer
after successful surgical treatment. If the blood CEA level is high, the patient is referred back to hospital by
their general practitioner for further investigation, usually a computerised tomography (CT) scan (a form
of radiography).
This study had two elements: a formal review of all previous studies describing the diagnostic accuracy of
blood CEA levels in identifying recurrent colorectal cancer and an analysis of new data recently collected
by a large multicentre UK trial of follow-up after surgery for colorectal cancer.
The results confirm current advice that measuring blood CEA levels should not be the only method of
post-surgery follow-up; adding a CT scan and colonoscopy during the first 12–18 months will help to avoid
missed cases of recurrence (although there appears to be no additional benefit from regular CT scans).
The results also suggest that the decision to refer for further investigation should be made on the basis of
the trend in CEA levels over time rather than the individual test results. This approach appears to be much
more accurate, reducing the number of missed cases of recurrence and the number of patients referred to
hospital for further investigation who prove not to have a recurrence.
Smokers should also quit or think twice about CEA follow-up – they are at significant risk of multiple false
alarms that would result in unnecessary investigations.
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Scientific summary
Background
Following primary surgical and adjuvant treatment for colorectal cancer, patients are routinely followed up
with blood carcinoembryonic antigen (CEA) testing for 5 years. The Follow-up After Colorectal Surgery
(FACS) trial showed that this follow-up is effective at detecting recurrences treatable with curative intent.
However, the optimal testing interval and method for interpreting test results lack a firm evidence base.
Our initial protocol was restricted to conducting a secondary analysis of CEA testing results from the
FACS trial. However, initial work revealed serious limitations of existing reviews of previous research
and so we also conducted a formal systematic review following Cochrane guidelines for identifying and
meta-analysing studies of diagnostic accuracy.
Aim and objectives
The main aim was to determine how the CEA test result should be interpreted to inform the decision to
undertake further investigation to detect treatable recurrences. Secondary objectives were to determine
whether or not diagnostic accuracy could be improved by (1) taking account of the baseline CEA level and
other pretest patient characteristics; (2) considering the trend in CEA levels over time; (3) considering
whether recurrence occurred early or late in follow-up; and (4) changing the testing interval.
Methods for the systematic review
Search
The search details are reported on the Cochrane website [http://onlinelibrary.wiley.com/doi/10.1002/
14651858.CD011134.pub2/full (last accessed 6 November 2016)].
Studies included
Cross-sectional diagnostic test accuracy studies, cohort studies or randomised trials, conducted in primary
care or hospital settings, involving adults with no detectable residual disease after curative surgery (with or
without adjuvant therapy) and reporting results extractable in a 2 × 2 format (i.e. test +/– by case +/–).
Index test
The index test was the blood CEA level.
Reference standard
The reference standard was clinical diagnosis of recurrence of colorectal cancer following primary
treatment confirmed by imaging, histology or clinical follow-up [for details of the reference standard see
the full report on the Cochrane website: http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD011134.
pub2/pdf (accessed 25 August 2016)].
Analysis
Two review authors extracted data independently and three authors independently performed a Quality
Assessment of Diagnostic Accuracy Studies 2 assessment of the included studies, with subsequent
discussion to reach consensus on overall judgements of risk of bias and applicability. The meta-analyses
followed Cochrane guidelines for pooling test accuracy data.
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Methods for the main analysis
Design
This study involved a secondary observational analysis of data from the FACS trial, a 2 × 2 pragmatic
randomised factorial controlled trial comparing minimum post-surgery follow-up of colorectal cancer
patients for 5 years with 3- to 6-monthly blood tests for CEA and 6- to 12-monthly computerised
tomography (CT) imaging. We analysed the two arms of the trial that required CEA testing.
Statistical analysis
Receiver operating characteristic (ROC) analysis was implemented to compare the effect of making the
decision to trigger further investigation in individual patient on the basis of (1) the CEA level at each test;
(2) the difference between test and postoperative CEA levels (expressed both as an absolute value and as a
ratio); and (3) the trend in CEA levels over time. An operational analysis of the probable impact of CEA
testing if used prospectively in clinical practice was also conducted, hypothetically applying the four
most commonly reported thresholds in the systematic review (2.5, 5, 7.5 and 10 µg/l) to trigger further
investigation on the basis of each test carried out during the follow-up period. To investigate the diagnostic
accuracy of assessing trends in serial CEA measurements within an individual rather than simply interpreting
the most recent CEA measurement taken, linear regression models were fitted to the CEA values for each
individual over time. The distribution of slope coefficients for individuals who did and did not experience
recurrence were compared and ROC analysis was used to evaluate the diagnostic accuracy of CEA trend.
All analyses were carried out using the statistical package R [see www.R-project.org/ (accessed 25 August
2016)]; the ROC analysis was carried out using the R package pROC.
Participants
Patients who had undergone curative surgery for primary colorectal cancer and who, after extensive testing
(histology, imaging and a CEA level of ≤ 10 µg/l), were confirmed to have no residual disease were
recruited from 39 NHS hospitals across all regions of England. The analysis was based on 582 patients
from the two arms of the study that received CEA testing.
Carcinoembryonic antigen measurement
The CEA analysis was undertaken using a Siemens Centaur XP analyser (Siemens Healthcare, Erlangen,
Germany) at a single laboratory with a standard quality control regime to ensure longitudinal stability.
If the blood CEA level was ≥ 7 µg/l above the patient’s baseline level at trial entry after repeat
measurement, the general practitioner was asked to refer the patient urgently to the local hospital for
further investigation. The median number of CEA measurements available for each participant was 13
[interquartile range (IQR) 10–14], with a median of six (IQR 3–9) measurements in patients who developed
a recurrence and 14 (IQR 13–14) in those who did not develop a recurrence.
Diagnostic reference standard
The reference standard against which diagnostic accuracy was assessed was clinical diagnosis of recurrence
of colorectal cancer as determined by the colorectal cancer multidisciplinary team at the participating
hospital centre.
Results
Diagnostic accuracy of a single test
The diagnostic accuracy of CEA testing across all thresholds, estimated on the basis of all CEA tests carried
out prior to diagnosis, is modest [area under the receiver operating characteristic curve (AUC) 0.74, 95%
confidence interval (CI) 0.68 to 0.80]. Sensitivity is estimated as 50.0% (95% CI 40.1% to 59.9%). The
median lead time gained at a recommended threshold of 5 µg/l is about 3 months, but the predictive value
would be 62% assuming the same frequency of recurrence experienced in the trial, implying that about
four in 10 patients without a recurrence will have at least one false alarm. The positive predictive value of
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an individual test (rather than an individual patient) is even lower at 43.3% (95% CI 35.8% to 51.0%),
as some patients suffer repeated false alarms. For example, the 89 false alarms triggered at a threshold
of 5 µg/l were clustered in 29 individuals, 15 of whom (51.7%) would have more than one false alarm
and eight of whom would have more than five false alarms. Trying to improve the sensitivity of CEA
testing by reducing the threshold for further investigation has a high cost in terms of falling specificity.
Although sensitivity can be increased to 63.5% (95% CI 54.2% to 72.8%) by reducing the threshold to
2.5 µg/l, there is a sevenfold increase in the number of times further investigation is triggered and, in 84%
of cases, no recurrence is detected.
Adjusting for postoperative baseline carcinoembryonic antigen level
Adjusting the CEA level by an individual’s baseline measurement offers no notable improvement in
diagnostic accuracy. Of the 6623 CEA measurements in the database, 3881 (59%) were lower than their
baseline measurement and therefore had a negative ‘difference’ value or a ratio value of < 1; 19 patients
who developed recurrence always had a negative adjusted value (i.e. all of their CEA measurements were
lower than their baseline level).
Predicting missed cases and false alarms
None of the characteristics assessed (patient age and smoking status, site and stage of the primary tumour,
receipt of adjuvant therapy and delay in commencing monitoring and site of recurrence) significantly
increased the likelihood of recurrence being missed. However, current smoking was significantly predictive
of multiple false alarms (adjusted odds ratio 6.55, 95% CI 1.52 to 28.20; p = 0.01).
Diagnostic accuracy of trend
The AUC suggests that the rate of change of CEA level provides better overall discriminatory power than
the single-value CEA transformations explored (AUC for positive trend 0.85, 95% CI 0.78 to 0.91).
A negative trend (i.e. a reducing level of CEA post treatment) may also have diagnostic value, increasing
the AUC to 0.91; however, this improvement is not statistically significant. The optimal threshold for
interpreting trend changes over time, to achieve 70% sensitivity at around 90% specificity, falls from
1.75 µg/l in year 1 to 0.3 µg/l in year 5.
Diagnostic accuracy in early and late recurrence
Assessing trend performs better than single test assessment in detecting both early recurrence (recurrence
in the first 2 years after treatment) and late recurrence (recurrence in years 3–5), with little difference in
accuracy for each time period.
Test interval
At a single test threshold of 5 µg/l, the testing interval needs to be approximately halved in year 1 to ensure
that the number of recurrences detectable at each test, and, therefore, test operational performance,
remains fairly constant over time. The test interval also needs to be reduced in year 1 if action is to be taken
on the basis of trend [with a 3-monthly testing interval the CEA level would not be measured with any
precision until month 9, by which time 31 (29.8%) recurrences had already been diagnosed].
Relevance and implications
The importance of not triaging with carcinoembryonic antigen alone
Our main analysis confirms the findings of the systematic review: CEA testing alone is insufficient as a
triage test for colorectal cancer recurrence. Whatever threshold is applied to interpret the CEA test
result (based on a single test or trend), a significant number of patients will suffer recurrence without a
detectable change in CEA levels. This underlines the importance of combining CEA testing with scheduled
imaging, as recommended in most national guidelines.
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The advantage of making decisions on the trend in carcinoembryonic
antigen levels
The diagnostic accuracy of the trend in CEA levels, assessed by the slope (beta-coefficient) of the linear
regression line, was consistently better than interpreting the results of a single test, regardless of whether
the single test was adjusted for the baseline postoperative CEA level. The observation that optimal
performance was achieved by taking account of a negative as well as a positive trend merits further
investigation. It suggests that a slow post-treatment reduction in CEA level is itself a marker of recurrence.
The choice of carcinoembryonic antigen threshold
Both the systematic review and the main analysis highlighted the very high cost in terms of false alarms of
adopting an action threshold for a single test below the 5 µg/l commonly recommended by national
guidelines. The analysis of operational performance suggests that a higher threshold (of perhaps 10 µg/l) may
be preferable. Even using trend analysis, the number of false alarms suggests that aiming for a sensitivity of
70% – augmenting CEA testing with a colonoscopy and one or two CT scans to detect the missed 30%
of recurrences – may be the clinically preferable option. In applying the trend analysis, the main results also
highlighted the importance of not applying the same action threshold throughout the 5-year follow-up
period. It is important that thresholds derived from our data are checked and refined in an experimental
setting before being rolled out, but, as a starting point, we suggest initiating further investigation if the
rate of change in CEA level exceeds 1.7 µg/l/year in year 1, 1.4 µg/l/year in year 2, 0.8 µg/l/year in year 3,
0.5 µg/l/year in year 4 and 0.3 µg/l/year in year 5.
The choice of testing interval
The testing frequency in year 1 would need to be increased to achieve a more consistent level of
operational performance over time and to allow for an earlier assessment of trend. A testing schedule of
monthly for the first 3 months and then every 2 months for the rest of the year would be consistent with
our findings. Adopting this increased testing frequency would be challenging in some health-care systems
and would need careful planning (as it requires rapid turnaround of results, good communication with
patients and access to a clinician who is able to discuss and act on the results quickly). Although the falling
incidence of recurrence would suggest that testing frequency should be reduced to one test in year 5, this
would have implications for the achievable lead time.
Who should and should not be followed up with carcinoembryonic antigen
The main analysis of the FACS trial shows that CEA follow-up is appropriate for all patients who have
completed surgical and adjuvant treatment for their colorectal cancer and who have, on extensive
investigation, no sign of recurrence. It also shows that patients at Dukes’ stages A–C have a similar
incidence of treatable recurrence and obtain similar benefit. There is no suggestion that patient age, the
characteristics of the primary tumour or the recurrence site predict either missed cases from non-response
or false alarms. However, the likelihood of multiple false alarms is significantly higher in smokers,
suggesting that CEA is not an appropriate follow-up method for patients who continue to smoke.
Other research implications
The systematic review drew attention to the poor quality of the majority of diagnostic studies on CEA
testing. Moreover, virtually all studies assessed CEA as a single diagnostic test, ignoring the fact that it is
used as a monitoring test and is carried out repeatedly over time. Even the Cochrane diagnostic accuracy
methodology that we used to conduct the systematic review considers only single test results, not trend
over time. This issue should be addressed, not just in relation to CEA testing but in relation to all tests that
are repeated over time to monitor disease progression. The need to refine the suggested cut-off points for
monitoring CEA trend (by conducting pilot implementation studies before large-scale roll-out) has already
been mentioned. In conducting these studies, it might be preferable to use a reference standard based on
recurrence treatable with curative intent rather than any recurrence.
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Chapter 1 Introduction
International guidelines recommend that, after completion of primary surgical treatment for colorectalcancer, blood carcinoembryonic antigen (CEA) levels are measured at 3- to 6-monthly intervals for
5 years to detect recurrent cancer.1–5 CEA is a glycoprotein involved in cell adhesion, which is produced
during foetal development; production usually ceases at birth, but elevated blood levels can be detected in
colorectal cancer (as well as in breast, lung and pancreatic cancer), smokers and benign conditions such as
cirrhosis of the liver, jaundice, diabetes mellitus, pancreatitis, chronic renal failure, colitis, diverticulitis,
irritable bowel syndrome, pleurisy and pneumonia.6,7 Blood CEA levels are raised in most patients at first
diagnosis of colorectal cancer and are thought to be detectable between 4 and 8 months before the
development of cancer-related symptoms.8 CEA levels fall after successful primary curative treatment but
then tend to rise again if the cancer recurs. It has been suggested that CEA appears to be most sensitive for
detecting hepatic and retroperitoneal metastases and is least sensitive for local recurrences and peritoneal
or pulmonary disease.9,10 However, the CEA blood level gives no information about the location and extent
of recurrence and it is therefore used as a diagnostic triage test, with a rise in CEA triggering further
investigation [usually by computerised tomography (CT) imaging] rather than initiation of therapy.1
The evidence base to support CEA follow-up is limited. The one Cochrane review estimating the
effectiveness of colorectal cancer follow-up11 included very scant data on CEA. Data on overall survival were
available from only one trial [odds ratio (OR) 0.57, 95% confidence interval (CI) 0.26 to 1.29] and data on
recurrence rate were available from only two (OR 0.85, 95% CI 0.58 to 1.25). We reported the interim
results of the FACS (Follow-up After Colorectal Surgery) trial in 2014.12 The results showed that measuring
blood CEA every 3 to 6 months for 5 years, augmented by a single CT scan at 12–18 months, leads to
earlier diagnosis of recurrence and increases by about threefold the proportion of recurrences that can be
treated with curative intent. As CEA monitoring does not involve radiography, it can be carried out in the
community and is potentially more cost-effective than CT imaging. However, the optimal interval for
monitoring blood CEA and the blood level at which further investigation is initiated appear not to have a
clear evidence base.
The research reported here was commissioned as an add-on component of the FACS trial. In the FACS
trial, which was designed in 2001, further investigation to look for recurrence was initiated if the patient’s
CEA level was 7 µg/l above their postoperative baseline level. Although the test result was confirmed by a
repeat test, no notice was taken of previous results. Most national guidelines cited above now recommend
taking action at a lower threshold (5 µg/l) but still focus on a single test result and take no notice of trend.
Moreover, the most recent systematic review at the time that we proposed this substudy13 suggested
that an even lower threshold of 2.2 µg/l provides the ideal balance between sensitivity and specificity.
We therefore sought to assess whether the threshold we had been using in the trial was suboptimal and
had impacted negatively on our results. We also hypothesised that focusing on an individual test and
ignoring trend over time was likely, on first principles,14 to be a suboptimal approach to monitoring.
The research specified in the original protocol was restricted to a secondary analysis of data from the
FACS trial. As we began the research and reviewed the original papers, it became clear that the review by
Tan et al.,13 cited above, was both incomplete and had a number of methodological flaws. As we had
used this review to justify our proposal, we felt obliged to conduct a more rigorous systematic review of
previous work, applying the quality criteria for systematic reviews of diagnostic accuracy specified by the
Cochrane Diagnostic Review Group.15 This work has now been published in full on the Cochrane Library
website16 but, as it was initiated to guide the research described here (in terms of both analytical method
and interpretation of the results), we provide a summary of the findings in Chapter 2 before presenting the
aims, methods and results of the main analysis.
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The FACS trial was not powered to assess the effect of CEA testing on survival but it is important to note
here that, although it provides clear evidence that 3- to 6-monthly CEA monitoring increases significantly
the number of detected recurrences treatable surgically with curative intent, the CIs around the mortality
outcome (at a median of 8.7 years from trial entry) show that any survival benefit must be small. The rate
of recurrence in the FACS trial was also significantly lower than that in the diagnostic studies reported in
the systematic review, reflecting the level of work-up before trial entry to detect residual disease.
INTRODUCTION
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Chapter 2 Systematic review
Parts of this report are based on Shinkins et al.17 This is an open access article distributed under theterms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use,
distribution and reproduction in any medium, provided the original author and source are credited.
Introduction
As stated in the previous chapter, this review was initiated when it became clear that the systematic review
cited in justification of our funding application13 was potentially flawed. To ensure that our systematic
review was carried out to the highest quality standard, it was undertaken under the auspices of the
Cochrane Colorectal Cancer Group and the Cochrane Screening and Diagnostic Tests Methods Group
(which refereed both the protocol and the results). We present the results here, before the main analysis,
as they informed the thresholds investigated in the analysis as well as the way in which we interpreted our
results. As these results have been published in full on the Cochrane Library website,16 we present only a
summary of the methods and main findings.
Methods
Review question
The review question was, ‘What is the accuracy of single-measurement blood CEA as a triage test to
prompt further investigation for colorectal cancer recurrence after curative resection?’.
Search
The search terms used are reported on the Cochrane Library website.16 We avoided the use of search filters
and did not restrict our review to English-language publications. Two reviewers (BN and IP) extracted data
independently and, with a third reviewer (BS), independently assessed the methodological quality. We
retrieved and analysed all full-text articles that we felt could be potentially relevant based on the title and
abstract. We based additional searches on the citations of full-text articles to reduce the risk of missing
relevant studies. Foreign-language articles were translated or assessed or both by colleagues of the authors
who were proficient in the language in question.
Studies included
The following studies were included: cross-sectional diagnostic test accuracy studies, cohort studies or
randomised trials, conducted in primary care or hospital settings, involving adults with no detectable
residual disease after curative surgery (with or without adjuvant therapy) and reporting results extractable
in a 2 × 2 format (i.e. test +/– by case +/–).
Index test and reference standard
The index test was blood CEA level. The reference standard was clinical diagnosis of recurrence of
colorectal cancer following primary treatment confirmed by imaging, histology or clinical follow-up
(for details of the reference standard, see the full report on the Cochrane website16).
Quality assessment
Two review authors extracted data independently and three authors independently performed a quality
assessment [using a modified Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2) schedule18]
of the included studies, with subsequent discussion to reach consensus on overall judgements of risk of
bias and applicability.
Statistical analyses
Binary diagnostic accuracy data were extracted from all excluded studies as 2 × 2 tables. We used the bivariate
model to perform meta-analysis of sensitivity and specificity19 using the xtmelogit command in Stata version 12
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(StataCorp LP, College Station, TX, USA).20 The quality assessment was used to identify the probable sources of
heterogeneity (including threshold) and subgroup analyses and meta-regression were implemented to explore
these factors.
As an exploratory analysis, we estimated the absolute numbers of false alarms (false positives) and missed
cases (false negatives) per 1000 patients tested for each 3-monthly testing interval by applying the pooled
sensitivity and specificity derived from this review to (1) the observed median reported prevalence of
recurrence divided by 15 (because a recommended schedule of 3-monthly testing for 2 years followed
by 6-monthly testing means that, typically, 14–15 tests are undertaken during 5 years of follow-up) and
(2) the incidence of recurrence data per follow-up period reported by Sargent et al.21 (because in reality the
proportion developing recurrence between tests is not constant but falls over time).
Results
Main findings
We identified 52 studies amenable to meta-analysis, including in aggregate 9717 participants [median sample
size 139, interquartile range (IQR) 72–247]. The median proportion of recurrences in each study was 30% (IQR
24–36%). The diagnostic accuracy of CEA was reported at 15 different thresholds, ranging from 2 to 40 µg/l.
Diagnostic accuracy at the most commonly recommended threshold in national guidelines of 5 µg/l
(23 studies, 44%) is shown in Figure 1. The filled black circle indicates that the pooled sensitivity is 71%
(95% CI 64% to 76%) and the specificity is 88% (95% CI 84% to 92%). Each box in the figure
represents the 2 × 2 data extracted from each study. The width of the box is proportional to the number of
patients who did not experience recurrence in each study and the height is proportional to the number of
patients who did develop recurrent colorectal cancer. The smaller dashed ellipse represents the 95%
credible region around the summary estimate; the larger dashed ellipse represents the 95% prediction
region for individual study estimates.
Implications of applying other thresholds
In the seven studies that reported accuracy at a threshold of 2.5 µg/l, the pooled sensitivity was 82%
(95% CI 78% to 86%) and the specificity was 80% (95% CI 59% to 92%). Seven studies also reported
accuracy at a threshold of 10 µg/l, with a pooled sensitivity of 68% (95% CI 53% to 79%) and a
specificity of 97% (95% CI 90% to 99%). Table 1 shows the implications of applying these thresholds in
clinical practice, assuming a 2% incidence of recurrent disease in each testing interval. The estimate of 2%
is based on an observed median prevalence of recurrence of 30% in the studies included in this review
and on national guidance to conduct 14 or 15 CEA tests during follow-up.22
Implications of applying current UK national guidelines
Table 2 shows the clinical implications of applying the recommended absolute CEA threshold of 5 µg/l to
trigger further investigation at each recommended test during 5 years of follow-up, applying the pooled
estimates of sensitivity and specificity to the most recently published estimates of the number of cases of
recurrence occurring in each test interval21 rather than the constant 2% incidence rate derived from the
studies included in the review. As the sensitivity estimate applied is constant and independent of the
number of cases of recurrence, the reported small differences in the percentage of cases missed reflects
rounding; they are included to highlight the limited sensitivity of the test. The rate of false alarms (people
investigated who do not have a recurrence) is dependent on the number of recurrences at each time point
but the difference between the time points (range 78–92%) is less striking than the high level of false
alarms at every time point if the recommended threshold of 5 µg/l is applied.
Quality and robustness
The subgroup analyses to assess the impact of variance in quality and analytical method applied by
included studies focused on the 5 µg/l threshold. The two possible approaches to constructing the
2 × 2 tables (i.e. evaluate the CEA measurement taken closest to the time point at which recurrence was
detected or look across all measurements to assess whether or not any had crossed the threshold during
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the entire follow-up period) gave similar estimates of test performance: the estimated sensitivity was
69.0% and 64.5% and estimated specificity was 90.0% and 89.5%, respectively.
Although we were unable to carry out a subgroup analysis based on specific laboratory techniques
because of incomplete reporting, we were able to compare studies carried out before and after the
TABLE 1 Clinical implications of applying different absolute CEA thresholds to trigger further investigation
assuming a 2% incidence of recurrent disease in each testing interval
Threshold (µg/l)
Studies
(participants), n
Sensitivity
(95% CI) (%)
Specificity
(95% CI) (%) Implications for 1000 people tested
2.5 7 (1515) 82 (78 to 86) 80 (59 to 92) 16 cases of recurrence detected and four
cases missed, 196 people referred
unnecessarily for further testing
5 23 (4585) 71 (64 to 76) 88 (84 to 92) 14 cases of recurrence detected and six cases
missed, 118 people referred unnecessarily for
further testing
10 7 (2341) 68 (53 to 79) 97 (90 to 99) 14 cases of recurrence detected and six cases
missed, 29 people referred unnecessarily for
further testing
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FIGURE 1 Summary receiver operating characteristic (ROC) plot of CEA accuracy at detecting recurrence at a
threshold of 5 µg/l (reference standard clinical diagnosis of recurrence confirmed by imaging, histology or clinical
follow-up; see the Cochrane Library website16 for full details of authors’ definitions). This figure is a copy of
Figure 8 in the review; copyright is held by the Wiley Online Library and it is reproduced with their permission
(http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD011134.pub2/full; last accessed 6 November 2016).
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introduction of the International Reference Preparation (IRP) 73/601 calibration.23 Before the introduction
of the IRP, the pooled sensitivity was 73.6% and pooled specificity was 88.5%; after IRP introduction,
pooled sensitivity was 67.9% and pooled specificity was 88.6% (95% CI 80.0% to 93.7%). The effect of
the covariate in the meta-regression was non-significant (p = 0.96).
Restricting the analyses to the studies deemed to be at low risk of bias in the patient selection, index test,
reference standard and timing/flow domains of the QUADAS-2 assessment made little difference to the
estimates of pooled sensitivity and specificity and, when the risk of bias in each domain was added
as an ordinal covariate in the meta-regression analysis of diagnostic accuracy, the effect on the model
was non-significant (patient selection p = 0.77; index test p = 0.90; reference standard p = 0.29;
flow/timing p = 0.66).
Discussion
Differences from the review cited in the original application
The systematic review cited in the original application13 identified only 20 studies and reported the
accuracy of CEA for the diagnosis of colorectal cancer recurrence using the Moses–Littenberg method.24
We identified more than twice as many studies and implemented the bivariate meta-analyses recommended
in the Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy.16,19,25 This is a statistically
more rigorous method that directly accounts for the correlation between sensitivity and specificity. However,
our pooled estimate of specificity at a CEA threshold of 5 µg/l was the same as that of Tan et al.13 (88%).
Although our pooled estimate for sensitivity was noticeably higher than that of Tan et al.13 (71% vs. 63%),
the variance around both estimates means that the difference is not statistically significant.
TABLE 2 Clinical implications of applying the recommended absolute CEA threshold of 5 µg/l to 1000 patients
tested at each recommended time point
Month of CEA test
Estimated
recurrences, n
Referred with high
CEA level, n Cases detected, n
Cases missed,
n (%)
False alarms,
n (%)
3-monthly testing, years 1 and 2
3 19 131 13 6 (31.6) 118 (90.1)
6 19 131 13 6 (31.6) 118 (90.1)
9 39 143 28 11 (28.2) 115 (80.4)
12 39 143 28 11 (28.2) 115 (80.4)
15 37 142 26 11 (29.7) 116 (81.7)
18 37 142 26 11 (29.7) 116 (81.7)
21 31 138 22 9 (29.0) 116 (84.1)
24 31 138 22 9 (29.0) 116 (84.1)
6-monthly testing, years 3–5
30 46 147 33 13 (28.3) 114 (77.6)
36 36 142 26 10 (27.8) 116 (81.7)
42 27 136 19 8 (29.6) 117 (86.0)
48 25 135 18 7 (28.0) 117 (86.7)
54 17 130 12 5 (29.4) 118 (90.8)
60 14 128 10 4 (28.6) 118 (92.2)
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The method used by Tan et al.13 to identify 2.2 µg/l as the ‘optimum’ CEA threshold was based on linear
extrapolation beyond the data (the lowest threshold included in their study was 3 µg/l). We now question
the recommendation of 2.2 µg/l (which was based on achieving high sensitivity), not just on the basis of
the low specificity (and high false-alarm rate), but also because there appears to be a ‘ceiling’ effect in
terms of sensitivity; even at a threshold of 2.5 µg/l, around one in five cases of recurrence would be
missed. The failure to exceed a sensitivity of about 80% even with a low threshold and poor specificity
reflects the well-documented fact that some recurrent cancers are not associated with a rise in blood
CEA level. Our interpretation of the data is therefore that (1) the use of an absolute single test threshold
should be questioned; (2) if an absolute single test threshold is applied, it should be higher than the level
of 5 µg/l recommended in most national guidelines, using another monitoring modality in parallel with
CEA level (such as a single CT scan at 12–18 months) to deal with the ‘sensitivity gap’ – trying to increase
sensitivity by lowering the CEA threshold achieves little at high cost.
Limitations of the review
The major limitation of the review is the quality of the studies included. There was also considerable
between-study variation in the reporting of factors known to impact on CEA level (e.g. stage of primary
disease included, approach to ensuring no residual disease, reporting of smoking, reporting of
chemotherapy treatment, and the location of recurrence). Over half of the included studies were at high
risk of selection bias, mainly because of inappropriate patient exclusions. The methods used to measure
CEA were also poorly reported: three studies (6%) did not report the CEA threshold used to determine a
positive result, 15 studies (29%) did not report which laboratory technique had been used and 43 studies
(83%) failed to report any indicator of method accuracy or an estimate of CEA test reproducibility.
The reference standard was also inadequately described in many studies. In nine studies the reference
standard was assessed only if a rise in CEA was detected, raising the possibility of verification bias.
Furthermore, most studies implemented a composite reference standard but failed to report consistently
which investigation (within the composite) actually diagnosed recurrence; in half of these studies, positive
results for certain reference tests triggered the use of other reference tests. Although three studies were
assessed as having no risk of bias or applicability concerns, they reported accuracy at different CEA
thresholds, implemented different CEA laboratory techniques and used differing composite reference
standards to detect recurrence. It was therefore infeasible to provide pooled diagnostic accuracy estimates
restricted to these studies.
The time between the CEA measurement and the reference test used in the 2 × 2 table was not reported
in any of the studies. There is therefore a high chance of misclassification because of disease progression
during the time between the CEA test and the reference test. Understanding this relationship is important
because (1) a high-grade recurrence will progress more quickly than a low-grade recurrence and (2) this
information is required to estimate lead time. Furthermore, no study reported 2 × 2 data for each 3- to
6-month period of follow-up, which would be desirable given that the incidence of recurrence falls over
the 5 years of follow-up.
Implications for the main analysis
Despite the difference between our findings and those of Tan et al.,13 in most aspects the review
underlined the importance of the questions and analysis set out in our protocol. It highlighted a number of
methodological aspects of the FACS study data, including four key strengths: CEA measurement was
centralised in a laboratory with high-level quality assurance, the time between index test and diagnosis is
known, the reference standard was quality assured [by local oncology multidisciplinary teams (MDTs)] and
we obtained data on recurrence and test performance at each testing point during the scheduled 5 years
of follow-up. It also highlighted an unanticipated weakness, namely the potential for verification bias.
In the FACS trial, the threshold for triggering further investigation was 7 µg/l. When we submitted the
application we assumed that our interest would be limited to thresholds below this level. The review
meant that this was not the case.
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Before we undertook the review, we were less clear about the plateau effect on sensitivity (i.e. decreasing
the absolute threshold does not increase sensitivity above what appears to be a maximum achievable value
of about 80%). This finding made us expand the planned analysis to investigate whether factors other
than preoperative CEA level could characterise in advance those at high risk of experiencing recurrence
without a rise in CEA. The high rate of false alarms identified by the review also reminded us of the
importance of characterising test performance in terms of predictive value as well as sensitivity and
specificity. The failure of previous studies to report and adjust for factors other than cancer recurrence that
are known to influence CEA levels also encouraged us to investigate the potential of such adjustment to
improve test performance.
We had already specified in the original protocol that we would investigate (1) whether making the
decision to investigate further on the basis of the trend in CEA levels over time, rather than the absolute
level of a single test, would provide better diagnostic accuracy and (2) whether the recommended testing
intervals in national guidelines (commonly every 3 months for 2 years and then every 6 months for 3 years)
are optimal. The review reminded us that these two issues are likely to be interdependent. It also reminded
us of the limitations of retrospective analysis in predicting clinical performance over time. We therefore
augmented the static analytical method described in the original protocol by attempting to model real-time
performance prospectively.
Implications for future research (other than our main analysis)
The generic outcome from this review is the overall poor quality of reporting of diagnostic accuracy studies
in this field. This poor reporting is compounded by the considerable between-study heterogeneity and
limitations of study quality. In response to the methodological limitations highlighted in this review,
authors of future research investigating the diagnostic accuracy of CEA should take care to report the CEA
threshold and technique used, with an indication of method accuracy and CEA reproducibility; the time
point at which the CEA level is measured; the reference test used; and the time between the CEA test and
the reference test.
The lack of significant improvement in diagnostic accuracy following a sensitivity analysis limited to studies
at low risk of bias (based on a QUADAS-2 assessment) also suggests that modifications to the QUADAS-2
schedule may be warranted in assessing the quality of diagnostic tests used for follow-up monitoring. Any
future studies commissioned would be more useful if augmented by a cost–benefit analysis of different
strategies for the timing of monitoring tests and the optimal combination of CEA blood testing and
CT imaging.
SYSTEMATIC REVIEW
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Chapter 3 Main study: aim and objectives
Main aim
The main aim was to determine how CEA test results should be interpreted to inform the decision to
undertake further investigation to detect treatable recurrences of colorectal cancer.
Other objectives stated in the protocol
The protocol listed four other objectives:
1. to determine how CEA test results should be interpreted to inform the decision that risk of recurrence is
sufficiently low that no further follow-up is necessary
2. to determine the extent to which the performance of CEA testing in detecting recurrence or cure
postoperatively is dependent on the extent to which the tumour secreted CEA preoperatively,
as indicated by the preoperative CEA level
3. to determine whether or not the recommended CEA testing interval is appropriate
4. to determine whether or not the diagnostic accuracy of CEA testing is different in late recurrence
(> 3 years after surgery).
Simplified objectives
These specific objectives are interdependent and underpinned by the same methodology for estimating
diagnostic accuracy. In reporting the results we have therefore simplified them, presenting in turn our
investigation of the:
1. diagnostic accuracy of CEA testing as a single diagnostic test
2. factors that may affect the diagnostic accuracy of CEA (including preoperative CEA level)
3. diagnostic accuracy of the trend in CEA level over time
4. diagnostic accuracy of CEA testing for detecting early compared with late recurrence
5. optimal testing interval.
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Chapter 4 Main study: methods
Design
This study consisted of a secondary observational analysis of data from the FACS trial, a 2 × 2 pragmatic
randomised factorial controlled trial comparing minimum post-surgery follow-up of colorectal cancer
patients for 5 years with 3- to 6-monthly blood tests for CEA and 6- to 12-monthly CT imaging.12
We analysed the two arms of the trial that required CEA testing.
Participants
Participants were recruited from the centre at which they received their primary treatment, spanning
39 NHS hospitals across all regions of England. To be eligible for the study, participants had to have
undergone curative surgery for primary colorectal cancer and, after extensive testing (histology, imaging
and a CEA level of ≤ 10 µg/l), to be confirmed to have no residual disease. Further detail regarding the
study setting, participant inclusion and exclusion criteria and randomisation procedures can be found in
the original publication.12
The CEA-only arm (n = 300) involved measurement of blood CEA every 3 months for 2 years, and then
every 6 months for 3 years, with a single chest, abdominal and pelvic CT scan at 12–18 months. The CEA
and CT arm (n = 302) involved the same CEA measurement schedule but, in addition, chest, abdominal and
pelvic CT scans were carried out every 6 months for the first 2 years and then annually for the following
3 years. Overall, compliance with scheduled CEA follow-up schedule was high (70.6% of patients never
missed a test) but 20 patients were removed from the data set as they did not have any CEA measurements
(10 died before the first CEA test was scheduled, nine withdrew from the trial and one was not tested for
reasons unknown), leaving 582 patients in the analysis. The participant flow chart is shown in Appendix 1
(see Figure 9).
Carcinoembryonic antigen measurement
Blood CEA levels measured prior to trial entry were assessed at local laboratories. Only 157 patients
(27.0%) had a preoperative CEA level but 569 (97.8%) had a postoperative level.
After recruitment to the trial, blood collection kits were sent directly to the patients, who then attended
their own general practice for phlebotomy. Blood samples were sent to the biochemistry laboratory at
the John Radcliffe Hospital, Oxford; the CEA analysis was carried using a Siemens Centaur XP analyser
(Siemens Healthcare, Erlangen, Germany).
If the blood CEA level was ≥ 7 µg/l above a patient’s baseline level at trial entry the test was repeated as soon
as possible; if the second test was also above this threshold the general practitioner was asked to refer the
patient urgently to the local hospital for further investigation. All CEA measurements taken after recurrence
had been clinically diagnosed (35 CEA measurements in total, affecting 23 unique individuals) and 30 repeat
measurements taken to confirm an increase in CEA of ≥ 7µg/l were excluded from this analysis.
The median number of CEA measurements available for each participant was 14 (IQR 10–14), with a
median of five (IQR 2–9) measurements in patients who developed a recurrence and 14 (IQR 13–14) in
those who did not develop a recurrence. The total number of CEA measurements available for analysis at
each time point is shown in Appendix 1 (see Table 11).
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Diagnostic reference standard
The reference standard against which diagnostic accuracy was assessed was clinical diagnosis of recurrence
of colorectal cancer as determined by the colorectal cancer MDT at the participating hospital centre.
The evidence on which this diagnostic decision was based was case specific, but, in the vast majority
of cases, involved CT scans of the chest, abdomen and pelvis plus other investigations (e.g. blood
biochemistry, pathology results, colonoscopy, other site-specific imaging) as appropriate. As investigation
for suspected recurrence could be triggered for reasons other than a raised CEA level (e.g. suspicious
symptoms or abnormal results on colonoscopy or CT imaging), the diagnostic modality that first triggered
investigation for recurrence was recorded.
Statistical analysis
Evaluating the diagnostic accuracy of carcinoembryonic antigen level as a
single diagnostic test
To evaluate the accuracy of CEA for diagnosing recurrence based on the data from the FACS trial, receiver
operating characteristic (ROC) curves are presented alongside 95% bootstrap CIs using the pROC package
in R version 3.1.3 (The R Foundation for Statistical Computing, Vienna, Austria).26 CIs were calculated using
2000 stratified bootstrap replicates. The areas under the receiver operating characteristic curves (AUCs) are
also reported. Sensitivity and specificity, likelihood ratios and predictive values (along with their respective
95% CIs) are summarised for the most commonly recommended and implemented threshold of 5 µg/l.
In contrast to the traditional diagnostic accuracy paradigm in which only one measurement is taken,
in this scenario we evaluated multiple CEA measurements taken within a single individual. Two alternative
methods for evaluating the accuracy of CEA testing were identified in our Cochrane review: some studies
reported the accuracy of the CEA measurement closest to the time at which recurrence was detected by
the reference standard, whereas others defined the CEA level as positive if any CEA measurement crossed
the threshold at any time within the follow-up period. As the latter method better represents how CEA
levels are interpreted in practice, that is, CEA is monitored and all CEA measurements are interpreted
prospectively, we applied this method in the analyses here.
For comparison with the results of the Cochrane review, we also report as a secondary analysis results
based on the measurement taken closest to the time at which recurrence was detected. For patients who
did not experience recurrence, the CEA measurement taken at the end of follow-up was evaluated.
An operational analysis of the probable impact of CEA testing if used prospectively in clinical practice was
also conducted, hypothetically applying the four most commonly reported thresholds in the systematic
review (2.5, 5, 7.5 and 10 µg/l) to trigger further investigation on the basis of the result of each individual
test carried out during the follow-up period. Two outcomes are reported: (1) the proportion of recurrences
that would have been missed and not referred for further investigation because the CEA level was below
the threshold and (2) the proportion of patients with a CEA level above the threshold who were subject to
a false alarm (i.e. an unnecessary referral for further investigation of a patient who did not experience
recurrence throughout the whole follow-up period). The data for the 7.5-µg/l and 10-µg/l thresholds are
less robust than those for the 5-µg/l and 2.5-µg/l thresholds, as these thresholds were above the action
threshold applied in the FACS trial and therefore were influenced more by work-up bias.
We also calculated for each individual the lead time (i.e. the number of days earlier that the CEA test
would have triggered further investigation compared with the reference standard) by applying different
thresholds retrospectively. As a CEA value of 7 µg/l triggered further investigation within the trial,
we could look only at thresholds up to this level. The median lead time across all individuals, alongside
the proportion of recurrences detected earlier than by the reference standard, is presented.
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Evaluating the diagnostic accuracy of baseline-adjusted carcinoembryonic
antigen testing
The aim of this analysis was to ascertain whether or not individualising the interpretation of CEA results by
adjusting for each individual’s postoperative CEA measurement improves the diagnostic accuracy of CEA
testing. Two methods of adjustment were compared: (1) taking the difference between the CEA level at
each time point and each individual’s postoperative CEA level and (2) using the ratio between the CEA
level at each time point and each individual’s postoperative CEA level.
Comparative ROC curves are presented, again assuming that the CEA test was positive if any CEA
measurement crossed the threshold at any time within the follow-up period. The AUC for each interpretation
method is also reported. The median lead time and proportion of false alarms (as previously defined) were
compared across interpretation methods by selecting fixed levels of sensitivity (ranging from 60% to 80%).
Evaluating the effect of preoperative carcinoembryonic antigen levels on
the subsequent performance of carcinoembryonic antigen testing to detect
recurrence during follow-up
Because of the limited number of preoperative CEA measurements available, a comparative ROC analysis
broken down by preoperative CEA level was not possible. Instead, we report a very simple 2 × 2 analysis
taking the difference between individuals’ CEA levels at the time that recurrence was diagnosed (i.e. when
it should be most elevated) and their preoperative CEA levels and using a threshold of 2.5 µg/l.
Exploring factors that may predict missed cases and false alarms
The following factors were included in this analysis: (1) patient characteristics (age and smoking status);
(2) primary tumour characteristics [colon or rectum, N stage (number of nearby lymph nodes involved) and
whether treated with chemotherapy or radiotherapy]; (3) the time elapsing between surgery and the first
follow-up CEA measurement; and (4) the site of recurrence.
The relationship between these variables and a ‘missed case’ (defined here as a patient suffering a
recurrence without a rise in CEA level above 5 µg/l) and a ‘false alarm’ (defined here as a patient who does
not have a recurrence during the follow-up period but who has at least one CEA measurement above
5 µg/l) was explored. Univariate relative risks are reported alongside adjusted ORs derived by logistic
regression in which all of the listed explanatory variables have been forced into the model. These analyses
were carried out in Stata version 12.
Diagnostic accuracy of trend in carcinoembryonic antigen measurements
over time
To investigate the diagnostic accuracy of assessing the trend in serial CEA measurements within an
individual rather than simply interpreting the most recent CEA measurement taken, linear regression
models were fitted to the CEA values for each individual over time. For those patients who recurred during
the follow-up period, all CEA measurements up to the point at which recurrence was detected were
included in the model. For patients who did not recur during the follow-up period, all measurements
available were modelled. Patients who recurred in the first 6 months were excluded from these analyses,
as there were insufficient measurements to depict a trend.
The distribution of slope coefficients for individuals who did and did not experience recurrence was compared
and ROC analysis was implemented to evaluate the diagnostic accuracy of CEA trend. The preliminary analysis
reported in 201427 suggested that we should not restrict the analysis to downwards trend.
In practice, trends in CEA measurements would be evaluated prospectively and modelling all of the available
CEA measurements for those who do not go on to recur does not represent what would happen in clinical
practice. To overcome this and to ensure that the results better represent what would occur in clinical
practice, we have broken down the ROC analysis by year of recurrence so that only the measurements that
would be available up to that year are included in the linear regression models.
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Optimal testing interval
The optimal testing interval was explored in two ways: (1) by estimating the lead time (the time elapsed
between the rise in CEA level that triggers further investigation and the confirmation of a diagnosis of
recurrence) that would potentially be gained by initiating further investigation at different CEA levels; and
(2) by describing when recurrences occurred during the 5-year follow-up period. The number of recurrences
potentially detectable during each 3- or 6-monthly testing interval (i.e. the interval between any two CEA
tests) was then estimated by subtracting different amounts of lead time (0, 3, 6 and 9 months) from the
actual time elapsed between the start of follow-up and the actual date of confirmation of recurrence.
MAIN STUDY: METHODS
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Chapter 5 Main study: results
The characteristics of patients enrolled in the FACS trial, the recurrence rates and the pattern ofrecurrences have been described in detail elsewhere.12 The individual plots of CEA values over time for
each patient who suffered a recurrence are included in Appendix 1 (see Figure 10).
Diagnostic accuracy of carcinoembryonic antigen level as a
single diagnostic test
Figure 2 shows that the diagnostic accuracy of CEA testing across all thresholds, estimated on the basis of
all CEA tests carried out prior to clinical diagnosis of recurrence, is modest (AUC 0.74, 95% CI 0.68 to 0.80).
The green shading highlights the 95% CI around the ROC curve.
Table 3 presents the sensitivity, specificity, likelihood ratios and predictive values of blood CEA level at the
threshold of 5 µg/l, which is commonly recommended in national guidelines.
Many of the studies identified in the Cochrane review considered only the final CEA value before the
confirmation of recurrence. In our data set, this improved the AUC (0.80, 95% CI 0.75 to 0.86) but,
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FIGURE 2 Receiver operating characteristic plot showing the accuracy of any rise in CEA level above threshold.
Sensitivities and specificities achieved at thresholds of 2.5, 5, 7.5 and 10 µg/l are highlighted (reference standard:
recurrent cancer as assessed by the local hospital MDT).
TABLE 3 Estimated accuracy of a blood CEA level of > 5 µg/l for detecting recurrence in the FACS study
Accuracy measure Value (95% CI)
Sensitivity (%) 50.0 (40.1 to 59.9)
Specificity (%) 93.3 (90.6 to 95.3)
Positive predictive value (%) 61.9 (50.6 to 72.1)
Negative predictive value (%) 89.6 (86.5 to 92.0)
Positive likelihood ratio 7.5 (5.1 to 11.0)
Negative likelihood ratio 0.5 (0.4 to 0.7)
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interestingly, made minimal difference to sensitivity (final value 49% vs. all values 50%). As this method of
analysis does not represent how CEA measurements are interpreted in clinical practice (all measurements
taken are interpreted), the higher estimate of specificity (97.5%) is potentially misleading as it
underestimates the proportion of false-positive results.
A positive predictive value of 62% (based on the observed 17.9% recurrence rate) implies that about four
in 10 patients without a recurrence will have at least one CEA test result above the threshold of 5 µg/l.
The 89 false alarms triggered at a threshold of 5 µg/l were clustered in 29 individuals, 15 of whom (51.7%)
would have more than one false alarm and eight of whom (27.6%) would have more than five false alarms.
The proportion of false alarms also increased over time, from 34.5% in year 1 to 94.5% in year 5, which is
consistent with the falling incidence of recurrence.
Choosing the threshold for further investigation
The ROC curve in Figure 2 shows that trying to improve the sensitivity of CEA by reducing the threshold
for further investigation has a high cost in terms of reduced specificity. The impact on missed cases and
false alarms of either reducing the recommended threshold from 5 µg/l to 2.5 µg/l (or increasing it to
7.5 µg/l or 10 µg/l) is shown in Table 4. A breakdown of this table for each test point (according to the
currently recommended follow-up schedule) is available in Appendix 1 (see Tables 12 and 13).
Although the estimated sensitivity is increased to 63.5% (95% CI 54.2% to 72.8%) by reducing the
threshold to 2.5µg/l, there is a sevenfold increase in the number of times that further investigation is
triggered and, in 84% of these cases, no recurrence is detected. Increasing the threshold to 10 µg/l
substantially reduces the number of positive tests (by approximately six times) and false alarms (to < 10%)
but at a cost of increasing the proportion of missed cases (to 75%, 95% CI 66.7% to 83.3%).
Figure 3 estimates the impact of adopting different CEA thresholds (x-axis) on the median lead time that
can be gained (y-axis). Figure 3 is also annotated to show for each potential CEA cut-off point (at 1-µg/l
intervals) the proportion of potentially detectable recurrences that we estimate would be detected.
It suggests that the commonly used threshold of 5 µg/l achieves a lead time of about 3 months. It also
suggests that setting a lower test threshold would achieve a greater lead time (e.g. if a CEA value of 2.5 µg/l
was implemented to trigger further investigation, the median lead time might be increased to 6 months).
However, there is a high cost in terms of false alarms (see Table 4).
The effect of baseline carcinoembryonic antigen level and other
pretest patient characteristics
Baseline adjustment
Figure 4 compares the diagnostic accuracy of adjusting the CEA value for the baseline (postoperative) level
with the diagnostic accuracy of simply interpreting the CEA result. The ROC curves for each method of
TABLE 4 Missed cases and false alarms associated with different CEA thresholds based on an analysis of 6609
individual tests over the 5-year follow-up period
Outcome 2.5 µg/l 5 µg/l 7.5 µg/l 10 µg/l
CEA above threshold, n (%) (of 6609 tests) 1097 (16.6) 157 (2.4) 50 (0.8) 28 (0.4)
Missed cases, n (%) (of 104 recurrences) 38 (36.5) 56 (53.8) 65 (62.5) 78 (75.0)
False alarms,a n (%) (of tests above threshold) 924 (84.2) 89 (56.7) 4 (8.0) 2 (7.1)
a False alarms are patients who are recurrence free and who are referred unnecessarily for further investigation.
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interpretation substantially overlap, as do the 95% CIs around the estimates of the AUCs, suggesting that
adjusting the CEA value by an individual’s baseline measurement offers no notable improvement in
diagnostic accuracy.
Interpreting the baseline-adjusted CEA level is complicated by the fact that CEA levels appear to continue
to fall after the ‘baseline’ postoperative test. Of the 6611 CEA measurements in the database, 3344 (51%)
were lower than their baseline measurement and therefore had a negative ‘difference’ value or ratio values
of < 1. Nearly one-quarter (133/582, 22.9%) of patients always had a negative-adjusted value (i.e. all of
their CEA measurements were less than the baseline), of whom 116 remained recurrence free but 17
developed recurrence.
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FIGURE 3 Median lead time between a CEA test result and the confirmation of recurrence applying different
thresholds for instigating further investigation. Dashed lines show 95% bootstrap CIs.
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FIGURE 4 Receiver operating characteristic plots comparing the diagnostic performance of the single test
baseline-adjusted CEA value (expressed as a ratio and difference) with that of the unadjusted CEA value (reference
standard: recurrent cancer as assessed by the local hospital MDT).
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Effect of baseline adjustment on lead time and false alarms
Table 5 reports the estimated median lead time across a fixed range of sensitivity levels from 50% to 80%
for the two baseline-adjusted CEA values (difference and ratio) compared with the unadjusted CEA
value. It also shows the percentage of recurrence-free patients who are unnecessarily referred for
further investigation (false alarms). When considering plausible levels of sensitivities, using a baseline
transformation is akin to lowering the positivity threshold.
Adjusting for presurgery carcinoembryonic antigen level
It has been suggested that individuals who do not present with an elevated CEA level pre surgery are less
likely to produce elevated CEA levels during follow-up, despite the development of recurrence.28 Only
25 patients with recurrence in this analysis had a preoperative CEA measurement. Table 6 shows that
there is no indication that a low CEA level at the time of diagnosis of the primary tumour predicts CEA
level at the time of recurrence, indicating that the secretory behaviour of the recurrent tumour is not
determined by that of the primary tumour.
Predicting missed cases
The other characteristics of the patient and primary tumour assessed (e.g. patient age and smoking status,
site and stage of the primary tumour, receipt of adjuvant therapy, delay in commencing monitoring) were
equally unhelpful in predicting the likelihood of being a missed case (i.e. a patient suffering a recurrence
without a rise in blood CEA level above the 5 µg/l threshold). Although there was a potentially important
increase in missed cases in patients with delayed initiation of follow-up, it was not statistically significant
(adjusted OR 2.66, 95% CI 0.87 to 8.15; p = 0.09).
Predicting false alarms
Table 7 explores the possibility of predicting which patients are likely to experience false alarms with CEA
monitoring. Again, neither the site nor stage of the primary tumour, nor the site of recurrence, nor the
timing of the start of follow-up are significantly predictive of false alarms, although the CIs on these
TABLE 5 Median lead times and the percentage of false alarms at fixed levels of sensitivity when further
investigation is based on unadjusted and baseline-adjusted (difference and ratio) CEA levels
Sensitivity (%)
Unadjusted CEA Difference from baseline Ratio to baseline
Median lead
time (days)
False alarms
(%)a
Median lead
time (days)
False alarms
(%)a
Median lead
time (days)
False alarms
(%)a
80 267 76.3 336 80.7 336 80.7
75 237 76.2 325 80.8 325 80.7
70 235 74.4 344 80.0 335 79.9
65 214 70.7 211 76.3 267 77.9
60 191 66.4 217 70.0 237 75.8
55 139 56.8 187 63.0 167 63.2
50 72 44.5 104 47.2 143 59.4
a False alarms are patients who are recurrence free but who are referred unnecessarily for further investigation.
TABLE 6 Relationship between preoperative CEA level and CEA level at detection of recurrence
Preoperative CEA measurement
CEA measurement closest to point of recurrence detection
≤ 2.5 µg/l > 2.5 µg/l
≤ 2.5 µg/l 2 7
> 2.5 µg/l 5 11
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estimates are wide. However, current smoking is significantly predictive of multiple false alarms (adjusted
OR 6.55, 95% CI 1.52 to 28.2; p = 0.01). Current smokers have a 12% (95% CI 2.55% to 31.2%) chance
of experiencing more than one false alarm during 5 years of follow-up.
The diagnostic accuracy of the trend in carcinoembryonic antigen level
There were 42 individuals with fewer than three CEA measurements (76% of whom experienced recurrence).
Patients with only one CEA measurement (n = 23) were removed from the analyses, leaving 88 patients who
did develop recurrence and 471 recurrence-free patients. Patients with two CEA measurements (n = 19) were
included following a sensitivity analysis showing no significant impact on the effect of inclusion or exclusion.
The individual plots (see Appendix 1, Figure 10) for patients who developed recurrence show that there is
substantial variability, with only a minority displaying the anticipated pattern of a sharp rise in CEA level
following a period of stability. Of the 97 patients who had undergone at least two CEA tests prior to the
diagnosis of recurrence, six had a falling CEA level (and a further six had an initial fall before it began to
rise), 13 had a stable level and 23 had a rising CEA level but never exceeded the 5-µg/l threshold that
normally triggers further investigation. Even among the 55 patients whose CEA levels rose above 5 µg/l, in
23 patients the CEA rose gradually (over a period of 1–4 years) before it exceeded the threshold. The plots
in themselves suggest that the trend in CEA level may have more diagnostic value than an absolute
threshold for a single test.
TABLE 7 Ability of patient and tumour characteristics other than preoperative CEA level to predict multiple false
alarms (rise in CEA response > 5 µg/l on two or more tests without recurrence)
Characteristic n/N (%)
Univariate RR Adjusted OR
RR (95% CI) p-value OR (95% CI) p-value
Patient characteristics
Age (years) < 70a 6/245 (2) 1.58 (0.57 to 4.36) 0.38 1.26 (0.37 to 4.29) 0.71
≥ 70 9/233 (4)
Current smoker Noa 12/443 (3) 4.43 (1.34 to 14.7) 0.01 6.55 (1.52 to 28.21) 0.01
Yes 3/25 (12)
Primary tumour characteristics
Site of primary tumour Colona 12/338 (4) 0.44 (0.1 to 1.92) 0.26 0.64 (0.29 to 1.43) 0.28
Rectum 2/129 (2)
N stage 0a 12/353 (3) 0.53 (0.12 to 2.33) 0.39 1.06 (0.14 to 7.82) 0.95
1–2 2/111 (2)
Chemotherapy or
radiotherapy
Noa 11/283 (4) 0.53 (0.17 to 1.63) 0.26 0.43 (0.07 to 2.66) 0.36
Yes 4/195 (2)
Timing
Surgery to first follow-up
CEA test (months)
< 6a 4/106 (4) 0.75 (0.24 to 2.34) 0.62 0.78 (0.2 to 3.05) 0.72
≥ 6 10/354 (3)
RR, relative risk.
a Reference category.
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The individual plots also highlight two other important issues. First, the rise in CEA is not always smooth –
there is sometimes a dip in CEA level within a clear rising trend, presumably reflecting both within-person
variability and measurement error. Second, there is sometimes a significant delay between a CEA level
that would have triggered further investigation in the FACS trial and the confirmation of recurrence
(during which time patients have resumed CEA testing). This situation would have occurred when further
investigation did not initially detect the recurrence (indicating that CEA level may sometimes be a more
sensitive method for investigating recurrence than CT imaging).
Distribution of beta-coefficients
Figure 5 shows the distributions of the beta-coefficients (i.e. the gradient of the linear trend in the CEA
measurements) for the group of patients who did develop recurrence and the group who remained
recurrence free. The difference in variance around the mean of the two distributions is stark, indicating
much greater stability in CEA levels in patients who do not experience recurrence. For the recurrence-free
patients, the beta coefficients are centred on zero and show relatively little variability [mean 0.000006,
standard deviation (SD) 0.00003]. For patients who suffered recurrence, the distribution is much wider,
with a 100 times greater SD (0.0035 vs. 0.00003). Although the distribution for the patients who
suffered recurrence centres above zero (mean 0.001), indicating that a positive trend is more indicative of
recurrence, the extent of the variance suggests that a negative trend may also have some diagnostic value.
The distributions of the intercepts were also plotted (not shown) and heavily overlapped, indicating that
there is minimal discriminatory information contained in the intercepts of the linear regression models.
Diagnostic accuracy of a positive trend in carcinoembryonic antigen level
Figure 6 shows the ROC curve for basing the decision to investigate further on an increase in blood CEA
level over time (using the beta-coefficients from the individual patient linear regression models) rather than
on the result of a single test. The ROC curve shows a clear elbow towards the upper left-hand corner,
indicating that the slope in CEA level holds some discriminatory information for predicting recurrence.
The AUC suggests that the rate of change provides better overall discriminatory power than the
single-value CEA transformations explored so far (AUC 0.85, 95% CI 0.78 to 0.91).
A key limitation of this analysis is that it is retrospective and the beta-coefficients are based on all of the CEA
measurements (up to the point that recurrence is clinically detected). In clinical practice the decision to
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FIGURE 5 Distribution of regression coefficients of CEA levels in patients with and without recurrence.
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investigate will be made prospectively as results accrue. However, excluding CEA measurements taken closest to
the diagnosis of recurrence (up to 1 year) made no important or statistically significant difference to the AUC.
Effect of censoring
There is a trade-off in estimating CEA trend between improving the overall accuracy of the beta-coefficient
by including more measurements and diluting the effect of an increase in later measurements (i.e. if you
cumulatively include all measurements in calculating the regression line, if the CEA rise starts only late in
follow-up, a bigger CEA rise than at the beginning would be needed to shift the curve). The plots in
Appendix 1 (see Figure 10) show that a sudden late rise in CEA after a period of relative stability (i.e. an
‘elbow’ shape) was less common than a gradual slow rise and this is reflected in Table 8, which shows that
there is no obvious gain in censoring the number of CEA tests used to estimate the beta-coefficient.
If anything, ignoring earlier tests and calculating the slope only on the most recent tests reduces rather
than improves diagnostic accuracy.
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FIGURE 6 Receiver operating characteristic plot for the diagnostic performance of a positive trend in CEA level
(assessed by beta-coefficients derived by linear regression of CEA levels) (reference standard: recurrent cancer as
assessed by the local hospital MDT).
TABLE 8 Effect on the AUC of estimating the diagnostic accuracy of a positive CEA trend on only the most
recent measurements
Number of retrospective measurements included in the model AUC 95% CI
5 0.74 0.66 to 0.82
6 0.74 0.67 to 0.82
7 0.80 0.73 to 0.87
8 0.81 0.74 to 0.88
9 0.80 0.74 to 0.87
10 0.81 0.75 to 0.87
11 0.80 0.75 to 0.86
12 0.78 0.73 to 0.84
13 0.84 0.77 to 0.90
14 0.85 0.78 to 0.91
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Diagnostic accuracy of a trend in either direction
The beta-coefficients reflect the individual plots shown in Appendix 1 (see Figure 10); 13.6% of patients
with recurrence (n = 12/88) had a negative beta-coefficient, indicating that, overall, their CEA levels
showed a downwards trend during the follow-up period. Given that the distribution of beta-coefficients
for the recurrence-free group is tightly centred around zero, allowing a negative as well as a positive trend
to trigger further investigation further improves the AUC (0.91, 95% CI 0.87 to 0.96), but the 95% CIs
overlap substantially; thus, both the statistical and the clinical significance of this finding remain unclear.
Clinical application
As mentioned above, a key limitation of the accuracy evaluations of trend so far is that they have been
based on a retrospective analysis of all available measurements. Figure 7 shows the accuracy of
interpreting trends prospectively, as measurements are collected over the follow-up period. Based on the
AUCs, although there is some between-year variation in accuracy, assessing trends in CEA levels over time
still appears to be more accurate than interpreting just the most recent CEA measurement.
Diagnostic accuracy of carcinoembryonic antigen level in
detecting early compared with late recurrence
Figure 8 shows the diagnostic accuracy of the different approaches to interpreting CEA levels broken
down by whether the recurrence was detected early into follow-up (recurrence in the first 2 years after
treatment) or late (recurrence in years 3–5). As demonstrated above, interpreting trends in serial CEA
measurements (i.e. the beta-coefficient of a linear regression model) is more accurate than assessing single
CEA measurements for the detection of recurrence. The results in Figure 8 show that the accuracy of trend
is also less dependent on whether recurrence occurs early or late into follow-up. The accuracy of single
CEA measurements (particularly in those adjusted for baseline difference or ratio) is notably poorer for
early recurrences.
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FIGURE 7 Receiver operating characteristic curves showing the diagnostic accuracy of the trend in CEA level by
year of follow-up (reference standard: recurrent cancer as assessed by the local hospital MDT).
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Early recurrence
Late recurrenceAUC: 0.704 (95% CI 0.623 to 0.786)
AUC: 0.799 (95% CI 0.711 to 0.887)
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FIGURE 8 Receiver operating characteristic curves for different approaches to interpreting CEA levels in early and
late recurrence (reference standard: recurrent cancer as assessed by the local hospital MDT). (a) Single CEA
measurement: unadjusted; (b) single CEA measurement: difference from postoperative baseline level; (c) single CEA
measurement: ratio to postoperative baseline level; and (d) trend in CEA measurements over time. (continued )
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The test interval
Optimal test interval for a single test
Table 9 shows the mean number of recurrences detected in each year of the FACS trial and an estimate
of the number of recurrences detectable in each testing interval assuming (1) an equal distribution of
recurrence within the year; (2) that the current UK testing schedule of 3-monthly intervals in years 1 and 2
and then 6-monthly intervals in years 3–5 was used; and (3) that the CEA level will be above the CEA
threshold between 0 and 9 months prior to the FACS reference standard detecting recurrence. The results
are based on the actual threshold applied in the FACs trial of 7 µg/l.
The actual lead time that should be applied in interpreting Table 9 depends on the threshold used for
interpreting the test. For example, as Figure 3 shows, a threshold of 5 µg/l is associated with approximately
3 months of lead time. At this threshold, the testing interval needs to be halved in year 1 to ensure that
the number of recurrences detectable, and therefore test performance, remains fairly constant over time.
As the FACS trial follow-up stopped at 5 years, it is not possible to estimate in the same way the effect of
applying action thresholds of < 7 µg/l on the number of recurrences detectable in year 5. However, at this
threshold, the number of recurrences detected was less than half that in years 3 and 4. Although this
might suggest that the testing interval should be reduced from 6- to 12-monthly intervals to achieve
constant performance, this would constrain any potential diagnostic lead time gained.
Early recurrence
Late recurrenceAUC: 0.858 (95% CI 0.767 to 0.949)
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FIGURE 8 Receiver operating characteristic curves for different approaches to interpreting CEA levels in early and
late recurrence (reference standard: recurrent cancer as assessed by the local hospital MDT). (a) Single CEA
measurement: unadjusted; (b) single CEA measurement: difference from postoperative baseline level; (c) single CEA
measurement: ratio to postoperative baseline level; and (d) trend in CEA measurements over time.
TABLE 9 Mean number of new recurrences detectable at each scheduled CEA test assuming different amounts of
lead time
Outcome
Year
1 2 3 4 5
Number of recurrences confirmed 43 23 17 15 6
Mean number of new recurrences detectable at each scheduled CEA test
At point at which diagnosis was confirmed 10.75 5.75 8.5 7.5 3.0
3 months earlier 12.5 6.25 6.0 6.5 NA
6 months earlier 14.25 4.75 5.5 6.5 NA
9 months earlier 15.75 4.0 5.0 1.0 NA
NA, not assessable as data incomplete.
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Optimal test interval for carcinoembryonic antigen trend
Although trend was estimated on two measurements in 19 participants (as stated earlier), it is self-evident
that the beta-coefficient is assessed with increasing precision as more measurements accrue. In patients
without recurrence, this improvement in precision levelled off after about 10 measurements. It is also
self-evident that you cannot assess trend on the basis of a single measurement. This in itself implies the
need to increase the frequency of testing in the first year as, at present (with 3-monthly testing), trend
assessment would not be possible until 6 months and it would not be measured with any precision until
9 months, by which time 31 (29.8%) recurrences had already been diagnosed (and another 13 might
already have been detected if a 5-µg/l threshold had been applied).
The beta-coefficient lacks clinical face validity and could probably be implemented only within a
computerised algorithm, either calculating a risk of recurrence or giving dichotomous refer/do not refer
advice. Table 10 therefore presents the beta-coefficients in terms of change in CEA level per year.
It is clear from Table 10 that (1) the optimal threshold (to maintain the selected trade-off between
sensitivity and specificity) is not constant but falls over time and (2) to maintain a specificity of around 90%
it is necessary to accept a sensitivity of 70% rather than 80%. Aiming for a sensitivity of 80% means
accepting a level of specificity associated with a substantial number of false alarms.
The between-year instability in specificity estimates reflects the relatively small numbers contributing to the
analysis when it is stratified by year. CIs are not given to avoid complicating the table, but Figure 7 shows
that CIs around the AUCs for each year overlap.
TABLE 10 Specificity of CEA trend (expressed as change per year) at 70% and 80% sensitivity
Year
Sensitivity 70% Sensitivity 80%
Specificity (%) Change per year (µg/l) Specificity (%) Change per year (µg/l)
1 93.0 1.75 73.6 0.82
2 89.8 1.40 78.1 0.92
3 90.2 0.65 87.1 0.50
4 91.7 0.50 79.4 0.29
5 87.3 0.30 79.0 0.21
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Chapter 6 Discussion
Main findings
The importance of not triaging with carcinoembryonic antigen level alone
Our main analysis confirms the findings of the systematic review: CEA testing alone is insufficient as a triage
test for colorectal cancer recurrence. Whatever threshold is applied for interpreting the CEA test result
(based on a single test or trend), a significant number of patients will suffer recurrence without a detectable
change in CEA levels. This underlines the importance of combining CEA testing with scheduled imaging, as
recommended in most national guidelines. However, this does not imply that CT imaging has to be carried
out alongside every CEA test – in the comparative analysis of the FACS trial, combining 3- to 6-monthly CEA
testing with a single CT scan of the chest, abdomen and pelvis at 12–18 months achieved similar results in
detecting treatable recurrence as combining CEA testing with regular 6- to 12-monthly CT scanning.12
The advantage of making decisions on a trend in carcinoembryonic
antigen levels
The diagnostic performance of the trend in CEA level, assessed by the slope (beta-coefficient) of the linear
regression line, was consistently better than interpreting the results of a single test, regardless of whether
the single test was adjusted for the baseline postoperative CEA level. In particular, assessing trend detects
recurrence in patients with a slowly rising CEA level below the single test threshold. The main clinical
limitations of making decisions to further investigate on trend rather than on a single test result are that
(1) most recurrences occur early in the follow-up period when fewer test results have been accrued and
(2) it has less face validity than interpreting a single test result and will require the application of a computer
algorithm at the laboratory or testing facility. The observation that optimal performance was achieved by
taking account of negative as well as positive trends merits further investigation. It suggests that slow
post-treatment reduction in CEA level is itself a marker of recurrence.
The choice of carcinoembryonic antigen threshold
The systematic review highlighted the very high cost in terms of false alarms of trying to improve single-test
sensitivity by reducing the action threshold below the 5 µg/l commonly recommended by national guidelines.
The results of the main analysis confirmed that, even at this recommended threshold, more than half of
patients referred for further investigation will not have recurrence; decreasing the single-test threshold to
try to achieve the sort of sensitivity feasible by making decisions on trend would cause this false-alarm rate
to increase to ≥ 90%. Even using trend analysis, the number of false alarms suggests that aiming for a
sensitivity of 70% – augmenting CEA testing with another triage test such as a single CT scan to detect
the missed 30% of recurrences – may be the clinically preferable option. In applying the trend analysis,
the main results also highlight the importance of not applying the same action threshold throughout the
5-year follow-up period. For example, to achieve 70% sensitivity at a constant specificity of around 90%
requires the threshold applied to be reduced from 1.75 µg/l in year 1 to 0.3 µg/l in year 5. In applying such
thresholds, the current advice to use the same laboratory technique to avoid method bias error1 needs to be
endorsed (to minimise both false alarms and missed recurrence) and the CEA immunoassay techniques
require improved reproducibility in the 2.5–10 µg/l concentration range.
The choice of testing interval
More recurrences were detected at the beginning than at the end of the 5-year follow-up period.
Although this has been reported before, the finding remains important because the FACS cohort were so
thoroughly investigated for residual disease before trial entry. It implies that, ignoring the fact that static
test performance (i.e. sensitivity and specificity) also changes over time because of the characteristics of
presenting recurrences, operational performance (i.e. predictive value) will decline during follow-up.
This is at present reflected in the common practice of reducing CEA testing from 3-monthly intervals in
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years 1–2 to 6-monthly intervals in years 3–5. Our results suggest that this is not optimal. On the basis
of the number of detectable recurrences alone, testing would need to be carried out more frequently in
year 1 (arguably twice as frequently as in year 2). Increasing the frequency of testing in year 1 is also
important if the action threshold is to be based on assessing trend (as, at present, one-third of recurrences
occur before a trend is measurable). Adopting this increased testing frequency would be challenging in
some health-care systems and would need careful planning (as it requires rapid turnaround of results,
good communication with patients and access to a clinician who is able to discuss and act on the results
quickly). Although the falling incidence of recurrence would suggest that testing frequency should be
reduced to one test in year 5, this would have implications for the achievable lead time.
Who should not be followed up with carcinoembryonic antigen testing
It is not possible on the basis of any of the variables we assessed to predict in advance which patients will
fail to experience a rise in CEA level with recurrence and therefore should not be followed up by blood
CEA monitoring. There is no suggestion that patient age, characteristics of the primary tumour or the
recurrence site predict either missed cases from non-response or false alarms. However, the likelihood of
multiple false alarms is significantly higher in smokers, suggesting that CEA monitoring is not an
appropriate follow-up method for patients who continue to smoke.
Consistency with existing evidence
The modest sensitivity of CEA testing at the recommended 5-µg/l threshold is well documented, although
our estimate of 50% from the FACS data is even lower than the pooled sensitivity of 71% (95% CI 64%
to 76%) in our systematic review. This could reflect the efforts made to ensure that any residual disease
was identified (by rigorous postoperative investigation) before FACS trial entry and not labelled as
recurrence. We have criticised the meta-analytic method used by Tan et al.13 in their 2009 systematic
review, but for comparison they reported a sensitivity of 63% at a threshold of 5 µg/l and 84% at a
threshold of 2.2 µg/l. Our reported specificity is broadly consistent with that in previous studies, although
the impact on prospective operational performance (i.e. imaging workload and false alarms) will depend
on the testing interval and prevalence of recurrence in the population being followed up. We are not
aware of any previous studies estimating predicted operation performance to allow comparison with
our results.
The number of recurrences in the FACS trial of < 20% is similar to that reported in other recent trials of
adjuvant therapy such as the Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the
Adjuvant Treatment of Colon Cancer (MOSAIC) trial29 but less than that in the previous trials reported in the
review by Jeffery et al.11 and most of the diagnostic accuracy studies cited in our review.16 This almost
certainly reflects the completion of any adjuvant treatment and very intensive investigation for residual
disease that occurred prior to trial entry in the FACS trial. Nevertheless, consistent with recent adjuvant
trials,21 most recurrences were still detected in the first 18 months of follow-up, with very few occurring by
the final fifth year of scheduled follow-up. We therefore see no reason why our estimates of operative
performance of CEA testing in follow-up (such as false-alarm rates) and of the optimal testing interval and
threshold needed to maintain optimal performance levels are not generalisable to everyday clinical practice.
A number of previous studies have advocated the use of looking at the trend in CEA level during follow-up,
rather than trying to interpret the results of a single test. Almost 40 years ago, Minton and Martin30
suggested use of a nomogram to interpret serial test results and to guide the decision to undertake
second-look surgery, pointing out that this implied more frequent testing in the first 18 months. In 1985,
Staab et al.31 presented data supporting the proposal to make the decision to embark on second-look
surgery subject to the trend in three or four sequential CEA test results rather than a single test, also
pointing out that a rapidly rising level significantly reduced the chance of the recurrence being operable.
A Danish group replicated the findings of Staab et al.,31 constructing a simulation model using data on
295 patients drawn from a clinical trial;32 they confirmed that in many patients with recurrence, individual
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CEA values did not exceed 5 µg/l but test sensitivity could be increased to 70–80% (with a specificity of
80–90%) if the decision to investigate further was based on trend (CEA doubling time), but that test
frequency would need to be increased. The CEAwatch trial investigators published a review in 2011
summarising much of the relevant evidence and justifying their decision to adopt a dynamic threshold for
the CEAwatch trial (a 20% rise in CEA between two consecutive measurements).33–35
The only previous study that we could find that provides comparable data on the threshold that should be
applied in interpreting trend based on the regression coefficient was that by Boey.33 This study (based on
146 patients) reported that a sensitivity of 86% could be achieved by applying a threshold of a 5% rise
per month, but the specificity of this threshold was poor (76%). A recent report on interpreting CEA trend
in order to initiate positron emission tomography scans to detect recurrence is based on very small
numbers and does not report a comparable threshold.36 Interestingly, in the context of our finding that a
negative trend had diagnostic value, Ito et al.37 reported that a slow reduction in the CEA level following
primary surgical treatment was predictive of recurrence (presumably residual disease) in the early period
after primary surgery.
The problem of false alarms with current CEA thresholds has been raised recently by Litvak et al.38 based on
a review of 728 patients with resected colorectal cancer followed up at the Memorial Sloane Kettering
Cancer Center. They observed that almost 50% of patients (358/728) had a false-positive elevation above
the normal range based on single test results. However, they also observed that at levels of > 15 µg/l,
false-positive results were rare and there were no false positives if the CEA level was > 35 µg/l.
Strengths and limitations
Quality of carcinoembryonic antigen measurement
The main strengths of the FACS trial data in this context are that CEA testing was centrally managed with
high compliance with scheduled testing and all analyses were carried out in one laboratory with consistent
quality control. A key strength of this analysis, compared with previous diagnostic accuracy studies of CEA
for detecting recurrence of which we are aware, is that we modelled the operational performance of
CEA when used prospectively in clinical practice in addition to looking retrospectively at sensitivity and
specificity in relation to a series of tests.
Limitations of the reference standard
The main limitation of the data is that we do not have a reference standard at all time points. We do not
know the precise time when a recurrence would have been detectable by our reference standard.
Our estimate of unnecessary referrals is likely to be an underestimate as it includes only patients who did
not experience recurrence throughout the whole follow-up period. However, the length of follow-up and
within-trial surveillance means that we are unlikely to have missed cases of recurrence. Even if we had been
able to apply the reference standard at every time point, there may be a lead time between detectability of
recurrence by CEA testing and detectability of recurrence by imaging. The other limitation of the reference
standard that we report here (and which has been used by almost all previous studies of which we are
aware) is that it assesses the diagnostic performance of CEA testing in detecting any recurrence. We did not
have a sufficient number of cases of recurrence to stratify the analysis by the treatability of recurrence, as
only half of the patients in the FACS trial were allocated to CEA testing.
Work-up bias
The other important limitation is work-up bias. Patients in the FACS trial with a CEA level of > 7 µg/l above
their personal baseline were referred for further investigation. This relatively high threshold means that the
analyses of diagnostic accuracy at the thresholds of 2.5 µg/l and 5 µg/l are not subject to work-up bias, but
the estimates of operational performance at higher thresholds reported in Appendix 1 are less robust.
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Statistical precision and external validation
Although this is a relatively large diagnostic study, the limited number of cases of recurrence (n = 104)
limited the statistical precision of our estimates of sensitivity. The estimates based on statistical modelling
may also suffer from overfitting and merit external validation before clinical implementation.
Implications for clinical practice and research
Advantages of carcinoembryonic antigen testing as a triage test
Carcinoembryonic antigen testing has three great advantages over other forms of follow-up: it is relatively
inexpensive, it can be carried out in community settings and it does not expose the patient to radiation.
It can therefore be perfomed more frequently than other tests and has the potential to provide important
lead time in detecting recurrence (about 3 months at the currently implemented threshold). However,
our data underline that it cannot be used alone as a triage test because of its low sensitivity.
Clinical implications
Sensitivity can clearly be increased by reducing the threshold but, as stated above, the impact on workload
and high false-alarm rate make that a very unattractive solution. However, it is probably time to stop
defining the threshold for further investigation in terms of an absolute threshold. We have already shown
that much better diagnostic performance, including better sensitivity, can be achieved by considering trend
over time in a series of tests.27 This also implies that testing should be performed more frequently during
the first year of follow-up because almost half of the recurrences present during this early period.
Suggested monitoring schedule
The monitoring schedule that we suggest on the basis of our results is summarised in Box 1. The suggestion
that colonoscopy and CT of the chest, abdomen and pelvis may be a possible mechanism to increase
sensitivity to > 70% is based on the main analysis of the FACS trial. We suggest that evidence is now
sufficient to increase the testing interval in the first year and to adopt additional tests to maintain sensitivity.
We also think that the evidence on false alarms from the Cochrane analysis is sufficient to advise raising the
threshold for interpreting a single test from 5 to 10 µg/l and to advise smokers to quit or not be monitored
for CEA level. However, we suggest strongly that the implementation of interpreting CEA levels after
3 months on the basis of trend rather than individual level is staged so that optimal cut-off points can be
refined in one or two pilot sites before wider roll-out.
Other research implications
The systematic review drew attention to the poor quality of the majority of diagnostic studies on CEA
monitoring. Moreover, virtually all studies assessed CEA levels as a single diagnostic test, ignoring the fact
that it is used as a monitoring test performed repeatedly over time. Even the Cochrane diagnostic accuracy
review methodology focuses on single test results rather than monitoring performance. This issue needs to
be addressed, not just in relation to CEA testing.
As mentioned above, the most pressing further research is the need to conduct implementation studies to
refine the suggested cut-off points for monitoring CEA trend. In conducting this work, it would be
preferable to use a reference standard based on recurrence treatable with curative intent rather than
simply any recurrence.
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BOX 1 Suggested CEA monitoring schedule to detect recurrence after primary treatment of colorectal cancer
Testing interval
l Year 1: eight tests – months 1–3, monthly; months 4–12, every 2 months.
l Year 2: four tests – 3 monthly.
l Years 3–5: 6-monthly.
Interpretation method
Single test months 1 and 2, thereafter trend assessed by beta-coefficients.
Threshold for further investigation
l Single test: 10 µg/l.
l Trend (change per year): year 1, 1.7 µg/l; year 2, 1.4 µg/l; year 3, 0.8 µg/l; year 4, 0.5 µg/l; year 5, 0.3 µg/l.
Additional tests to maintain sensitivity
l One CT scan of the chest, abdomen and pelvis at 12 months (or one at 12 months and one at 18 months).
l Colonoscopy at 12 months.
Population to be monitored
All patients following surgical treatment of Dukes’ stages A–C colorectal cancer, after completion of adjuvant
treatment, with a CEA level of < 10 µg/l and no sign of residual disease on CT of the chest, abdomen and
pelvis and colonoscopy and who are non-smokers.
Smokers should be informed of the false-alarm risk and receive support to quit if they so choose (or be
followed up with a different modality).
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Appendix 1 Additional information
Recruits
(n = 602)
Randomised to
CEA-only arm
(n = 300)
Randomised to
CEA and CT arm
(n = 302)
Exclusions (n = 20)
• Postoperative deaths, n = 10
• Withdrawn, n = 9
• Lost to follow-up, n = 1
Followed up
(n = 582)
Non-recurrence
(n = 478)
Recurrence
(n = 104)
FIGURE 9 Flow chart of patients allocated to CEA testing within the FACS cohort to show the origin of the data
analysed here.
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FIGURE 10 Individual plots of CEA values in those patients who suffered recurrence. Both horizontal and vertical
scales vary to fit the data but the blue vertical line indicates the time of confirmation of recurrence and the green
horizontal line indicates a CEA level of 7 µg/l; ‘CEADay’ is the day after the start of follow-up on which the test was
carried out. (continued )
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FIGURE 10 Individual plots of CEA values in those patients who suffered recurrence. Both horizontal and vertical
scales vary to fit the data but the blue vertical line indicates the time of confirmation of recurrence and the green
horizontal line indicates a CEA level of 7 µg/l; ‘CEADay’ is the day after the start of follow-up on which the test was
carried out. (continued )
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FIGURE 10 Individual plots of CEA values in those patients who suffered recurrence. Both horizontal and vertical
scales vary to fit the data but the blue vertical line indicates the time of confirmation of recurrence and the green
horizontal line indicates a CEA level of 7 µg/l; ‘CEADay’ is the day after the start of follow-up on which the test was
carried out. (continued )
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FIGURE 10 Individual plots of CEA values in those patients who suffered recurrence. Both horizontal and vertical
scales vary to fit the data but the blue vertical line indicates the time of confirmation of recurrence and the green
horizontal line indicates a CEA level of 7 µg/l; ‘CEADay’ is the day after the start of follow-up on which the test was
carried out. (continued )
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FIGURE 10 Individual plots of CEA values in those patients who suffered recurrence. Both horizontal and vertical
scales vary to fit the data but the blue vertical line indicates the time of confirmation of recurrence and the green
horizontal line indicates a CEA level of 7 µg/l; ‘CEADay’ is the day after the start of follow-up on which the test was
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FIGURE 10 Individual plots of CEA values in those patients who suffered recurrence. Both horizontal and vertical
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FIGURE 10 Individual plots of CEA values in those patients who suffered recurrence. Both horizontal and vertical
scales vary to fit the data but the blue vertical line indicates the time of confirmation of recurrence and the green
horizontal line indicates a CEA level of 7 µg/l; ‘CEADay’ is the day after the start of follow-up on which the test was
carried out. (continued )
APPENDIX 1
NIHR Journals Library www.journalslibrary.nihr.ac.uk
48
(be)
C
EA
 v
al
u
e 
(µ
g
/l)
0
0
CEADay
27/450
1
2
3
4
5
6
8
9
10
11
12
7
500 1000 1500
(bf)
C
EA
 v
al
u
e 
(µ
g
/l)
0
100
CEADay
28/470
1
2
3
4
5
6
7
8
9
10
150 200 250 300 350
(bg)
C
EA
 v
al
u
e 
(µ
g
/l)
0
0
CEADay
29/479
2
4
6
8
10
12
14
16
18
500 1000 1500
(bh)
C
EA
 v
al
u
e 
(µ
g
/l)
0
100
CEADay
30/485
1
2
3
4
5
6
8
9
10
7
200 300 400
(bi)
C
EA
 v
al
u
e 
(µ
g
/l)
0
0
CEADay
31/491
1
2
3
4
5
6
7
8
9
10
50 100
(bj)
C
EA
 v
al
u
e 
(µ
g
/l)
0
0
CEADay
32/495
1
2
3
4
5
6
7
8
9
10
500 1000 1500
FIGURE 10 Individual plots of CEA values in those patients who suffered recurrence. Both horizontal and vertical
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FIGURE 10 Individual plots of CEA values in those patients who suffered recurrence. Both horizontal and vertical
scales vary to fit the data but the blue vertical line indicates the time of confirmation of recurrence and the green
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FIGURE 10 Individual plots of CEA values in those patients who suffered recurrence. Both horizontal and vertical
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FIGURE 10 Individual plots of CEA values in those patients who suffered recurrence. Both horizontal and vertical
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FIGURE 10 Individual plots of CEA values in those patients who suffered recurrence. Both horizontal and vertical
scales vary to fit the data but the blue vertical line indicates the time of confirmation of recurrence and the green
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FIGURE 10 Individual plots of CEA values in those patients who suffered recurrence. Both horizontal and vertical
scales vary to fit the data but the blue vertical line indicates the time of confirmation of recurrence and the green
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FIGURE 10 Individual plots of CEA values in those patients who suffered recurrence. Both horizontal and vertical
scales vary to fit the data but the blue vertical line indicates the time of confirmation of recurrence and the green
horizontal line indicates a CEA level of 7 µg/l; ‘CEADay’ is the day after the start of follow-up on which the test was
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TABLE 11 Number of blood CEA measurements available for analysis at each time point
Time point (months) CEA measurements, n
0 563
3 543
6 530
9 519
12 500
15 493
18 482
21 477
24 456
30 443
36 429
42 408
48 396
54 372
60 12
TABLE 12 Estimated operational performance of CEA testing in clinical practice at currently recommended intervals
if further investigation is triggered by thresholds of 2.5 and 5 µg/l
Time of test
CEA tests, n Recurrences, n
5 µg/l action threshold 2.5 µg/l action threshold
Year Month
Missed cases,
n (%)
False alarms,
n/Na (%)
Missed cases,
n (%)
False alarms,
n/Na (%)
1 3 563 15 9 3/15 7 63/88
6 542 17 10 6/16 10 68/92
9 530 7 3 2/9 2 68/87
12 519 12 7 8/15 3 66/86
All 2154 51 29 (56.9) 19/55 (34.5) 22 (43.1) 265/353 (75.1)
2 15 500 7 3 2/8 1 62/76
18 493 7 4 9/12 2 67/80
21 482 1 0 6/7 0 64/70
24 477 11 7 8/12 5 65/78
All 1952 26 14 (53.8) 25/39 (64.1) 8 (30.8) 258/304 (84.9)
3 30 455 6 4 7/10 4 67/76
36 444 7 1 9/16 0 68/80
All 899 13 5 (38.5) 16/26 (61.5) 4 (30.8) 135/156 (86.5)
4 42 427 6 2 6/11 0 71/81
48 408 5 3 7/9 2 69/74
All 835 11 5 (45.5) 13/20 (65.0) 2 (18.2) 140/155 (90.3)
continued
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TABLE 12 Estimated operational performance of CEA testing in clinical practice at currently recommended intervals
if further investigation is triggered by thresholds of 2.5 and 5 µg/l (continued )
Time of test
CEA tests, n Recurrences, n
5 µg/l action threshold 2.5 µg/l action threshold
Year Month
Missed cases,
n (%)
False alarms,
n/Na (%)
Missed cases,
n (%)
False alarms,
n/Na (%)
5 54 395 2 2 12/12 2 65/66
60 374 1 1 4/5 0 61/63
All 769 3 3 (100) 16/17 (94.1) 2 (66.7) 126/129 (97.7)
a The denominator in calculating the percentage of false alarms is the number of patients who would be referred for
further investigation; as patients in the FACS trial were not referred at this time point, the numerator is the number of
patients referred who never developed a recurrence at any time point. It is therefore not possible to sum across rows
(i.e. the number of recurrences does not equal the number of missed cases + the number of patients referred who were
not false alarms).
TABLE 13 Estimated operational performance of CEA testing in clinical practice at currently recommended intervals
if further investigation is triggered by thresholds of 7.5 and 10 µg/l
Time of test
CEA tests, n Recurrences, n
7.5 µg/l action threshold 10 µg/l action threshold
Year Month
Missed cases,
n (%)
False alarms,
n/Na (%)
Missed cases,
n (%)
False alarms,
n/Na (%)
1 3 563 15 11 1/8 13 0/2
6 542 17 10 0/8 13 0/4
9 530 7 4 0/5 4 0/3
12 519 12 7 0/6 8 0/4
All 2154 51 32 (62.7) 1/27 (3.7) 38 0/13 (0)
2 15 500 7 3 0/4 4 0/3
18 493 7 4 0/3 7 0/0
21 482 1 1 1/2 1 1/1
24 477 11 9 0/1 10 0/1
All 1952 26 17 (65.4) 1/10 (10.0) 22 1/5 (20.0)
3 30 455 6 5 1/2 6 1/1
36 444 7 2 1/2 2 0/5
All 899 13 7 (53.8) 2/4 (50.0) 8 1/6 (16.7)
4 42 427 6 4 0/6 4 0/2
48 408 5 3 0/2 4 0/1
All 835 11 7 (63.6) 0/8 (0) 8 0/3 (0)
5 54 395 2 2 0/0 2 0/0
60 374 1 0 0/1 0 0/1
All 769 3 2 (66.7) 0/1 (0) 2 0/1 (0)
a The denominator in calculating the percentage of false alarms is the number of patients who would be referred for
further investigation; as patients in the FACS trial were referred in accordance with the trial protocol, the numerator is
the number of patients referred who never developed a recurrence at any time point. It is therefore not possible to sum
across rows (i.e. the number of recurrences does not equal the number of missed cases + the number of patients
referred who were not false alarms).
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TABLE 14 Clustering of false alarms: number of patients who never recurred who would have a CEA measurement
over the threshold during the 5-year follow-up period
Threshold (µg/l)
Number of CEA measurements over the threshold
1 2 3 4 5 6 7 8 9 10 11 12 13 14 Total
2.5 42 18 13 7 7 3 7 5 9 4 10 8 11 12 156
5 14 5 1 1 2 2 1 0 1 2 0 0 0 0 29
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